Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
• Requisite clinical responses achieved in cohort 1 of Part A (1st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2
• Recruitment of cohort 2 of Part A of TACTI-002, additional 19 patients, will begin shortly
• Recruitment of the first cohorts of parts B and C continues
• Data from the ongoing TACTI-002 Phase II clinical trial will be presented at the 34th Annual Meetingof the Society for Immunotherapy of Cancer (SITC) in November 2019
Great news !
2.6c here we set
Immutep Announces Expansion of Part A of TACTI-002 Phase II...
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.005(1.27%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 41.0¢ | 38.5¢ | $963.3K | 2.418M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 43 | 201495 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 202151 | 14 |
View Market Depth
| Last trade - 13.59pm 03/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |